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Abstract Diabetic retinopathy is an increasingly prevalent
disease, and a leading contributor to the burden of all-cause
blindness worldwide. In addition to retinal changes, choroidal
abnormalities are common in patients with diabetes. The first
studies concerning this vascular structure were based on
histologic, indocyanine angiography and laser Doppler
flowmetry techniques, but the development of new optical
coherence tomography (OCT) technologies and imaging
software for enhanced depth imaging (EDI)-OCT in recent
years has made it possible to provide more detailed images
of the choroidal anatomy and topography.
In diabetic patients, several choroidal changes have been
described in the literature throughout the years; the recent
focus is choroidal thickness, which is significantly different
from that in healthy patients. However, understanding choroi-
dal manifestations of diabetic eye disease remains a real chal-
lenge, and this gap is hindering efforts towards better defining
choroidal evaluation as a predictive factor for disease evolu-
tion and treatment response.
This review aims to summarize the recent literature
concerning changes in choroidal structure in diabetic patients,
the relationship to diabetic retinal disease progression, and fi-
nally, the current and potential application of the measurement
of variations in choroidal thickness for patient management.
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Diabetic choroidopathy
Diabetic retinopathy (DR) is a leading cause of visual impair-
ment and blindness, affecting almost 35 % of all diabetic pa-
tients worldwide [1]. The main retinal insults are vascular and
neural, with vessel occlusion and leakage, leukostasis, and
alteration of the blood–retinal barrier as a result of dysfunc-
tional tight junctions, causing increased vascular permeability,
generation of free radicals, mitochondrial dysfunction, and
neuronal swelling and apoptosis [2]. The visual impairment
is attributed primarily to retinal damage, but evidence from
histologic, angiographic and laser Doppler flowmetry studies
suggests the simultaneous presence of diabetic choroidopathy
(DC). The choroid is an important vascular tissue, responsible
for the blood supply to the outer layers of the retina, including
the retinal pigmented epithelium (RPE) and photoreceptors,
and is the only source of metabolic exchange for the avascular
fovea [3]. The choroidal abnormalities in diabetic eyes include
microaneurysms, dilatation and obstruction of the choriocapillaris,
vascular remodelling with increased vascular tortuosity, vascular
dropout, areas of vascular non-perfusion and choroidal
neovascularization.
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Until recently, evaluation of the choroid was typically per-
formed using indocyanine green angiography (ICGA) or laser
Doppler flowmetry. These techniques, however, are only able
to show vascular abnormalities and are not able to provide any
information concerning anatomic and structural features of the
choroid.
With the recent development of spectral domain optical
coherence tomography (SD-OCT) and enhanced depth im-
aging (EDI)-OCT software, a more detailed evaluation of
the choroid became possible. The classical OCT devices
were unhelpful, as the RPE blocked the signal from the
choroid. By moving the peak of the sensitivity curve to
the sclera, maximizing sensitivity and detail, SD-OCT—
and EDI-OCT software in particular—provide a better
view of the choroidal cross-sectional structure, thickness
and choroidal–scleral interface [4]. This technique
launched a new era in choroidal evaluation and encouraged
further research on possible clinical applications for cho-
roidal thickness (CT) measurement. Nowadays, the role of
CT as a predictive factor of diabetic eye disease is almost
nonexistent. Nevertheless, a recent study reported that CT
may be useful for predicting short-term outcomes of anti-
vascular endothelial growth factor (VEGF) treatment in
patients with diabetic macular edema (DME), as greater
baseline CT was significantly associated with better visual
and anatomic outcomes after intravitreal anti-VEGF injec-
tions [5]. Research is ongoing in efforts to better under-
stand and to identify other possible roles for choroidal
changes that are seen, albeit inconsistently, in diabetic
patients.
The aim of this review is to summarize recent literature
regarding the use of the newer OCT technology for evaluation
of the choroid in diabetic patients, particularly CT and its
relation to the severity of DR.
Imaging the choroid
Histologic studies of diabetic patients have revealed many
changes consistent with vascular anomalies: atrophy and
loss of the choriocapillaris endothelium, capillary
narrowing and dropout, laminar deposits, tortuous and
beaded vessels, and choroidal neovascularization [6, 7].
In more advanced cases, even larger vessels have shown
onion-skin changes and aneurysmal formation [8]. They
were also found to be present in diabetic patients without
clinical DR, possibly clarifying the unexplained loss of
visual acuity in diabetic eyes without clinical evidence
of DR [6, 9].
Studies using fluorescein angiography and ICGA have
shown several filling abnormalities in diabetic eyes.
Reports of patients with mild non-proliferative diabetic
retinopathy (mNPDR) have described a characteristic
Bsalt-and-pepper^ pattern caused by selective filling of
the choriocapillaris, in contrast to the normal ground-glass
appearance [10]. Several other abnormalities have been ob-
served later in the disease course, notably hypofluorescent
spots and both small and large hyperfluorescent spots. These
abnormal patterns are well correlated with the severity of DR,
HbA1c levels and poor diabetes control [11–13].
An increased resistance index is seen when laser
Doppler flowmetry is used to access choroidal blood
flow beneath the fovea, possibly resulting from the
progressive reduction of choroidal blood flow and
volume in patients with diabetes, even in eyes with
clinically undetected DR [14, 15]. This suggests that
choroidopathy might trigger the development of
retinopathy due to retinal tissue hypoxia and overexpres-
sion of VEGF, contributing to further retinal damage and
macular edema. Reduced blood flow in the central
ophthalmic artery and vein was also found in diabetic
patients, with a steeper decrease in patients with
pro l i f e ra t ive d iabe t i c re t inopa thy (PDR) [16] .
Inconsistencies remain among published studies with re-
gard to choroidal blood flow measurements in diabetic
patients, as CT has been reported to be reduced (as stated
above), unchanged (particularly in the early stages of
diabetic disease) and even increased (mNPDR or untreat-
ed PDR) [17].
Recent developments in SD-OCT and EDI-OCT soft-
ware have allowed CT to be studied in many conditions.
Studies in normal eyes have revealed variations in CT
with age (decrease of 15.6 μm with each decade of life),
axial length (AL; −17 to −58.2 μm per millimeter of AL)
[18], and even time of day, with diurnal variation in CT
that can be as great as 67 μm [3, 19, 20]. In addition, the
thickness of the central choroid seems to increase with
progressive nasal and temporal thinning, a pattern that is
characteristic of all diabetic patients regardless of DR
grade [3, 21, 22]. Another OCT technology, swept-
source (SS)-OCT, uses a different light source and detec-
tion method, and offers the advantages of higher imaging
speed and accuracy, which are important in analyzing the
choroid [23–27]. Lastly, the recent development of OCT
angiography enables non-invasive visualization of vascu-
lar structures based on the motion of erythrocytes within
the retinal and choroidal vasculature. Given the impor-
tance of documenting choriocapillaris and choroidal vas-
culature in vivo, this technique will have a role in the
investigation of the choroid in both physiological and
pathological conditions [28, 29].
The advent of these technologies has facilitated a large
number of studies focused on the structure of the choroid in
diabetic patients, and recent results show a relevant associa-
tion between DR and CT.
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Diabetic choroidopathy: optical coherence
tomography
Decreased choroidal thickness
Many authors have found that decreased CT is associated with
diabetes [21, 22, 30–33], and some have suggested that this
might well relate to the instigated retinal insult—since the
choroid is the major source of oxygen and nutrition to the
outer layers of the retina and RPE, disturbances in this struc-
ture may lead to increased susceptibility to retinal tissue hyp-
oxia and ischemia seen in diabetes mellitus. Comparisons of
CTamong diabetic patients with mNPDR, DME and PDR has
revealed a trend towards significant choroidal thinning in eyes
with DR (Table 1).
Querques et al. [34] and Esmaeelpour et al. [30] reported a
significant decrease in CT among diabetic patients without
clinical evidence of retinopathy, suggesting that decreased
choroidal blood flow may be the primary event. These results
are consistent with the findings of vascular studies of the cho-
roid [15, 35]. Esmaeelpour, who used thickness maps of
36°x36° instead of single-point measurements, reported cho-
roidal thinning in an NDR group, particularly in the subfoveal
(p=0.001) and inferior regions (p=0.05). Furthermore, the
authors extended the thickness maps to the retina and reported
perimacular thinning, possibly caused by atrophy of the nerve
fiber layer, not visible with slit lamp examination. However, in
the presence of macular lesions (M1 and M2), there was no
apparent choroidal thinning directly below the lesions [30].
Increased choroidal thickness
Some data, however, disagree with the findings above, sug-
gesting that rather than thinning, the choroid may become
thicker in eyes with DR [32, 33, 36]. Kim et al., for example,
found significant choroidal thickening in eyes with DR, in-
creasing as the disease progressed in severity from severe
NPDR (sNPDR; p<0.05) to untreated PDR (p<0.01) [36].
These inconsistencies were justified by the authors as possible
differences in patient profiles and study limitations (see
below; Table 1). The study by Kase et al. somewhat agrees
with these findings, as their results show a non-significant
trend towards increased choroidal layer thickness with in-
creasing DR severity [37]. However, DR patients in that study
were subdivided into an under-treatment group receiving anti-
diabetic drugs and a no-treatment group, and only the no-
treatment group showed a significant change in CT, decreas-
ing in the mNPDR stage (p<0.05) and increasing posteriorly
in the sNPDR and PDR groups (p<0.05). Furthermore, DME
patients were not considered separately. These results suggest
that a chronic hyperglycemia may be a factor in further dete-
rioration of damaged choroidal microvasculature.
It is still unclear whether the choroidal changes are primary or
independent of the retinopathy. Some authors contend that pri-
mary choroidal angiopathy is present before the onset of DR,
while others believe these to be unrelated events [32, 33, 36],
with choroidopathy occurring only in more severe grades of DR
[21, 22, 24] or worsening with increasing DR severity [36, 37].
A recent study by Ferreira et al., which evaluated CT
among diabetic patients without DR, showed a significant
increase in CT at 1500 μm superior to the fovea (p=0.021).
None of the other 12 location comparisons were statically
significant (p>0.05; Fig. 1) [38]. These changes in CT may
well represent early pre-clinical changes in diabetic patients,
but the reason for the inconsistencies in the location and di-
rection of CT changes remains unknown.
Ferrara et al., who included 76 eyes in their recent study using
SS-OCT (22 eyes of 22 patients with DM but without DR, 20
eyes of patients with NPDR, 15 eyes with PDR, and 26 eyes of
healthy age-matched controls), detected vascular remodelling in
all DM patients corresponding to irregular, tortuous and beaded
choroidal vessels with focal dilation and narrowing. Small vessel
loss in the topography of previous retinal photocoagulation was
another relevant observation by the authors [39].
Choroidal thickness and diabetic macular edema
Uncertainties also exist concerning the connection between
the evolution of CT and increasing severity of diabetic reti-
nopathy. Some studies have found a correlation with increas-
ing DR severity [22], while others have found no correlation
between CT and grade of DR [21, 32, 40]. Thus the exact
relationship between CTand the severity of DR remains large-
ly unknown, and although some authors have cautiously sug-
gested choroidal thinning in areas with documented retinal
thickening (Querques et al. 2012; data not shown) [34], no
significant correlation between retinal and CT has been found
[21, 24, 33]. The exception is patients with macular edema
(with a thicker retina), who have clinically significant
subfoveal choroidal thinning compared to healthy eyes, but
have a tendency towards a thicker choroid when compared to
other grades of the disease, NPDR and PDR. While very few
authors have compared subgroups of diabetic patients given
the small samples in each group, Kim et al. reported signifi-
cant choroidal thickening in DME patients versus non-DME
patients (p<0.05). Furthermore, among DME patients, CT
appeared to be greater in the serous retinal detachment-type
(SRD-type) group than patients with cystoid-type macular
edema (p<0.05). These results are in agreement with other
observations of a tendency towards a thicker choroid in
patients with DME, although the difference was not signif-
icant [21, 22, 30–32]. Some authors, however, have cau-
tiously reported a thinner choroid in the presence of clini-
cally significant macular edema (CSME) [34, 35, 41],
explaining this pattern as an artefact induced by macular
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Table 1 Clinical studies
comparing subfoveal
choroidal thickness in
eyes with different
grades of diabetic disease
Study Number
of
patients
Method Groups SCT p value Valuable points/limitations
Esmaeelpour
[30], 2011
42 High-speed
3D-OCT
Control
NDR
M1
M2
CSME
327 ± 74
214 ± 55
208 ± 49
205 ± 54
211 ± 76
p < 0.001
p < 0.001
p < 0.001
p < 0.001
No relationship between
macular lesions and
choroidal thinning
Previous treatments
(PRP or anti-VEGF) were
not mentioned.
Esmaeelpour
[31], 2012
33 High-speed
3D-OCT
Control
NDR
DR
388 ± 109
291 ± 64
303 ± 82
p < 0.001
p < 0.001
Querques
[34], 2012
63 EDI-OCT Control
NDR
NPDR
NPDR/
CS-
ME
309.8 ± 58.5
238.4 ± 47.9
207.0 ± 55.9
190.8 ± 58.5
p < 0.001
p < 0.001
p < 0.001
PRP and anti-VEGF-treated
patients were excluded.
Regatieri
[21], 2012
49 HD-OCT Control
mNPDR
PDR
NPDR/
DME
232.3 ± 15.2
222.0 ± 21.6
162.7 ± 7.0
169.5 ± 14.7
NS
p < 0.001
p < 0.001
All DME patients had received
PRP more than 6 months
earlier; untreated PDR
patients were not included.
Cirrus HD-OCTwas less
accurate in identifying small
and focal lesions on the
choriocapillaris.
Vujosevic
[33], 2012
102 SD-OCT Control
NDR
NPDR
PDR
329.5 ± 65.2
280.6 ± 65.2
279.4 ± 81.6
230.5 ± 25.8
NS
p < 0.05
p < 0.05
Patients previously treated with
PRP or anti-VEGF drugs
were excluded.
Data on DME patients was not
shown.
Kim [36],
2013
235 EDI-OCT Control
NDR
mNPDR
sNPDR
PDR
276.0 ± 58.1
262.3 ± 68.4
244.6 ± 77.0
291.1 ± 107.7
363.6 ± 74.9
——
p < 0.01*
p < 0.01*
p < 0.05*
——
Patients with previous PRP
treatments were considered
separately, and eyes
previously treated with anti-
VEGF were excluded.
Patients with and without DME
were compared, disregarding
the grade of DR, and groups
with milder retinopathy
(NDR, mild NPDR) typically
had patients without DME,
as opposed to patients with
more severe DR that had a
greater number of DME
patients.
Lee [32],
2013
203 EDI-OCT Control
NDR
mNPDR
sNPDR
PDR
DME
228.5 ± 38.9
219.1 ± 47.8
158.9 ± 56.3
161.2 ± 38.5
157.4 ± 45.7
164.1 ± 63.0
NS
p = 0.05
p < 0.001
p < 0.001
p < 0.001
DME patients revealed no
significant differences in CT
compared to PDR and
sNPDR patients without
DME, but a slight trend
towards a thicker choroid.
There was no reference to
whether PDR patients
received PRP or anti-VEGF
treatment.
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edema, inhibiting the signal transduction and reflection
from the choroid due to increased ocular opacity. In
contrast, a study by Gerendas et al. reported that this CT thin-
ning was consistent among 142 eyes with DME, and that
Table 1 (continued)
Study Number
of
patients
Method Groups SCT p value Valuable points/limitations
Xu [40],
2013
246 SD-OCT Control
DM
250 ± 103
266 ± 108
P= 0.02 Comparisons to diabetic
patients ignored the presence
or absence of DR and its
grade.
There were few patients with
DR (23) among the 246
diabetic patients.
NDR
DR
251 ± 104
249 ± 86
NS
Adhi [24],
2013
33 SD-OCT Control
NPDR
PDR
DME
276.4
252.9
209.6
211.6
NS**
p < 0.05
p < 0.05
Anti-VEGF-treated DME
patients (57 %) were not
studied separately.
All eyes with PDR and DME
had received PRP, and time
between PRP and CT
measurement was ignored.
Blood pressure and HbA1c
values were ignored; groups
were not matched for axial
length.
Subgroups of DR were small.
Ünsal [22],
2014
151 EDI-OCT Control
mNPDR
PDR
NPDR/
DME
259.1 ± 13.1
235.4 ± 84.5
203.8 ± 47.6
206.8 ± 45.4
NS
p < 0.01
p < 0.01
All PDR patients had already
received PRP treatment, and
time between PRP and CT
measurement was not
considered.
Axial length, which affects CT
values, was not evaluated.
Kase [37],
2015
86 SD-OCT Control
NDR
mNPDR
sNPDR
PDR
DME
272 ± 72
255 ± 68
253 ± 81
309 ± 80
287 ± 71
276 ± 71
NS
NS
NS
NS
NS
None of the diabetic patients
received any PRP or anti-
VEGF treatment.
Subdivided DR patients into
groups receiving oral anti-
diabetic drugs and those
without therapy; only
patients in the no-treatment
group experienced
significant differences in CT
with increasing severity of
DR.
DME patients were not
considered separately.
Ferreira [38],
2015
125 EDI-OCT Control
NDR
240.6 ± 7.92
267.9 ± 6.16
p < 0.05 125 diabetic patients without
DR,
CT thicker at 1500 μm superior
to the fovea
SCT subfoveal choroidal thickness, NS not significant, NA not available, NDR no diabetic retinopathy, M1
microaneurysms within 1 disc-diameter of the fovea, M2 exudates within 1 disc-diameter of the fovea, CSME clinically
significant macular edema, DM diabetes mellitus, DME diabetic macular edema, NPDR non-proliferative diabetic reti-
nopathy,mNPDRmild tomoderate NPDR, sNPDR severe NPDR,PDR proliferative diabetic retinopathy,PRP pan-retinal
laser photocoagulation
*Compared with the PDR group
** Significant in other peripheral regions (see text)
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fellow eyes without macular edema were equally affected,
suggesting a systemic pathophysiologic mechanism [41].
Choroidal thickness after treatment for diabetic
retinopathy
The results discussed above should be interpreted with cau-
tion, however, as most patients included in PDR groups were
not treatment-naïve, and had already undergone pan-retinal
laser photocoagulation (PRP) or anti-VEGF treatment. In ad-
dition, the time between treatment and measurement of CT
was seldom mentioned. There is evidence that PRP may in-
duce long-term thinning of the choroid (possibly by downreg-
ulation of VEGF [36]), but in the short term (1 week), it may
be responsible for choroidal swelling, probably due to a
shifting of blood vessels from the peripheral retina to the fo-
veal area [42, 43]. Zhu et al. found significant thickening of
the subfoveal choroid 1 and 3 months after PRP, versus a
significant decrease in CT in the area subjected to photocoag-
ulation. In the latter, although scar formation may limit a local
inflammatory reaction, choroidal inflammation could induce
vasodilation of untreated areas, leading to an early increase in
CT [42]. Moreover, the effect of anti-VEGF drugs on CT is
still not well understood, although some studies have reported
choroidal thinning, at least in the first 6 months [44, 45]. Lee
et al. investigated changes in CT after intravitreal
bevacizumab injection, PRP or both for the treatment of DR,
and reported a decrease in CT after all treatments, suggesting
that both methods reduced choroidal vascular permeability
[46].
Other common limitations were a lack of consideration for
local variables influencing CT—particularly age, time of day,
and axial length/refractive error—as well as systemic condi-
tions that appear to alter the choroidal structure (see the
BOther factors^ section below). Some studies suggested the
influence of other variables on the visibility of the choroidal–
scleral interface (CSI) in OCT images and, consequently, CT
measurements. Notably, the study byGupta et al. suggested that
a well-defined CSI was present in only 60 % of subjects. The
variables believed to be responsible for this CSI measurement
b c
a
Fig. 1 Measurements of
choroidal thickness at 13
locations—subfoveal area (a) and
at 500-μm intervals from the fo-
vea to 1500 μm nasal (a),
1500 μm temporal (a), 1500 μm
superior (b) and 1500 μm inferior
(c)—in diabetic patients without
DR
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inaccuracy include axial length, age, diabetes, retinal thickness
and ocular opacities [47], which may thus help to explain dif-
ferences in results and findings among the clinical studies cited
in this review.
Others factors influencing choroidal thickness
In addition to local ocular factors, systemic conditions can influ-
ence CT. Control of blood hemoglobin A1c (HbA1c) appears to
be directly correlated with CT, as patients with lower baseline
HbA1c have shown a significant increase in CTafter strict blood
sugar control; however, no correlation was found between these
choroidal changes and fasting or average blood glucose [48].
In contrast, a significant correlation was found between CT
changes and systemic blood pressure control (systolic, diastolic
and mean arterial blood pressure) after 2 weeks of hospitaliza-
tion [49].
Hypertension is a known factor affecting the choroid
[49–51], and a recent study by Akay et al. found a significant
decrease in CT among patients with high blood pressure
(p<0.001), from 1000 μm nasally to 1500 μm temporally,
although there was no significant correlation between blood
pressure levels and duration of disease [51].
Hypercholesterolemia, on the other hand, was recently
found to cause a focal increase in CT, as reported by Wong et
al. The study showed increased CT in the subfoveal 1000-μm
nasal and 1000-μm superior areas, and is well supported by
animal models demonstrating atherosclerotic changes in the
choroid in the presence of high levels of serum cholesterol
[52]. Low triglyceride levels also appear to be related to a
thicker choroid, but the mechanism remains unknown [53].
All of these systemic imbalances are prone to atheroscle-
rotic changes, and frequently coexist in diabetic patients; thus
they warrant further consideration in future studies. However,
the complexity of their interactions makes it difficult to con-
template them as isolated variables, and so additional basic
studies in experimental models are needed.
Conclusion
Although it is clear that choroidal changes are present in pa-
tients with in diabetes, it remains unclear whether these changes
are predictive, modulatory, causative or independent factors for
DR, and the results from clinical studies remain inconsistent.
The majority of clinical findings supported by histology,
laser Doppler flowmetry and indocyanine green angiography
suggest choroidal thinning after the onset of diabetes in the
absence of clinical evidence of DR, whichmay account for the
visual defects reported by these patients. However, slightly
contradictory results, suggesting early thinning with later
thickening, or completely opposite results showing choroidal
thickening or the appearance of CTabnormalities in secondary
stages of DR, have also been obtained.
Differences in methods of choroidal evaluation may account
for these conflicting results, as vascular abnormalities are most
commonly found in media-peripheral regions, and OCT exams
tend to focus on the central macular/foveal region. In addition,
CT appears to be influenced by many factors other than the
severity of DR. A prior anti-VEGF or laser (PRP) treatment
was recently shown to have modulatory effects on choroidal
vessels; hence, the CT and time between treatment and mea-
surement should not be disregarded when designing clinical
studies. The presence of DMEmay also interfere with the mea-
surement of CT, or may even influence choriocapillaris func-
tion, as well as other local and systemic factors.
Lastly, although the pattern of diabetic choroidopathy-
related changes in CT is still not well understood, it may have
a predictive role for diabetic eye disease in the future. Studies
in age-related macular degeneration (AMD) have shown that
CTcorrelates with best-corrected visual acuity (BCVA), and is
helpful for predicting non-exudative disease and progression
of geographic atrophy as well as treatment response and visual
outcome in exudative AMD [54, 55]. Rayess et al. similarly
described a possible role for CT as a predictor of visual and
treatment outcome in patients with DME, as patients with
thicker CT had anatomic and functional responses [5].
In conclusion, with the advent of the latest OCT technolo-
gies, diabetic choroidopathy has become a highly studied clin-
ical entity garnering great interest among researchers.
Nonetheless, the relationship between DC and DR, and even
the role of DC in diabetic eye disease, remains unknown, and
further investigation is warranted.
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